While others have reported on the significant MACE reduction with GLP-1RA therapy in the secondary prevention cohort, but not in the primary prevention setting [91], our findings extend the current notion that the beneficial impact on the individual MACE constituents, particularly MI risk reduction, may be attenuated in the higher risk secondary preventative population with established CVD, often characterized by advanced age and multimorbidity status [90]
Time-restricted eating in adults with metabolic syndrome
Sim, desde que haja orientao de um profissional habilitado para garantir segurana e adequao s necessidades individuais
More recently, we reviewed five additional products and tested three powders
Most patients find an effective dose between 5 mg and 15 mg once weekly, but some may require adjustments based on their response and side effect profile
Akkermansia is not a replacement for GLP-1 medications, but it may help support the gut conditions tied to natural metabolic signaling, including mucosal integrity, SCFA production, inflammatory balance, and microbiome resilience